Personalis, Inc. (NASDAQ:PSNL) Stock Has Average Price Target of $14.54

Personalis, Inc. (NASDAQ:PSNL) has received an average rating of “Hold” from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $14.54.

A number of research analysts have recently weighed in on the company. Needham & Company LLC lowered Personalis from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Lake Street Capital downgraded Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a report on Monday, July 20th. TD Cowen reiterated a “buy” rating on shares of Personalis in a research report on Wednesday, July 15th. Morgan Stanley increased their price target on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Finally, Zacks Research raised shares of Personalis from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th.

Insider Buying and Selling at Personalis

In other news, CMO Richard Chen sold 3,998 shares of the stock in a transaction on Friday, September 18th. The shares were sold at an average price of $16.22, for a total value of $64,847.56. Following the sale, the chief marketing officer owned 169,882 shares in the company, valued at $2,755,486.04. This represents a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Stephen Moore sold 2,068 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $16.22, for a total transaction of $33,542.96. Following the transaction, the senior vice president directly owned 90,257 shares of the company’s stock, valued at approximately $1,463,968.54. This trade represents a 2.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 116,456 shares of company stock valued at $1,774,916 over the last quarter. Insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Personalis

A number of institutional investors have recently modified their holdings of PSNL. Merck & Co. Inc. purchased a new stake in Personalis in the 2nd quarter worth approximately $188,202,236. BlackRock Inc. purchased a new position in shares of Personalis during the 2nd quarter valued at approximately $94,905,000. Bank of America Corp DE purchased a new position in shares of Personalis during the 2nd quarter valued at approximately $24,395,000. AIGH Capital Management LLC acquired a new position in shares of Personalis in the 2nd quarter valued at $22,981,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Personalis by 8.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock valued at $6,791,000 after purchasing an additional 83,074 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Trading Down 0.7%

NASDAQ:PSNL opened at $16.17 on Friday. Personalis has a 12 month low of $4.95 and a 12 month high of $18.89. The firm has a fifty day simple moving average of $15.41 and a 200-day simple moving average of $11.37. The company has a market capitalization of $1.69 billion, a P/E ratio of -14.83 and a beta of 2.32.

Personalis (NASDAQ:PSNL) last released its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The firm had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. Equities analysts forecast that Personalis will post -1.07 EPS for the current year.

About Personalis

Personalis, Inc is a genomics company focused on precision oncology and advanced genetic testing. The company develops and commercializes molecular diagnostic products designed to help identify cancer-related genomic changes, monitor disease progression and support treatment decisions.

Its product portfolio includes the NeXT platform, which is used to analyze tumor and blood samples. Offerings have included tissue-based profiling, liquid biopsy testing and personalized minimal residual disease monitoring intended to detect small amounts of cancer remaining after treatment or to identify signs of recurrence.